Titlebook: Bortezomib in the Treatment of Multiple Myeloma; Irene M. Ghobrial,Paul G. Richardson,Kenneth C. An Book 2011 Springer Basel AG 2011 Borte

omnibus

褻瀆

xanthelasma

Niels Bugert,Maximilian Sch?pfel research due to its typical poor outcome. Besides a small subset of patients who can enjoy long-term disease-frees urvival through non-myeloablative allogenic stem cell transplant, most patients relapse and become frequently over time chemoresistant to conventional or high-dose cytotoxic-based ther

orthopedist

Favorable

Logistik in Wissenschaft und Praxis only applicable to approximately 20% of patients. Standard dose chemotherapy has included melphalan with dexamethasone. This regimen results in response rates in excess of 50%. With the introduction of IMID therapy, the combination of thalidomide or lenalidomide with dexamethasone has produced resp

FIG

bizarre

https://doi.org/10.1007/978-3-7643-8948-2Bortezomib; Cancer therapy; Multiple Myeloma; Oncology; Pharmacology; Proteasome inhibitors; Velcade; Apopt

upstart

Springer Basel AG 2011

懶惰民族

同步左右